CD33 and acute myeloid leukemia: In addition, CD47, CD33/CD3 antibody, FLT3 inhibitors and autophagy inhibitors (ROC-325) are also being investigated for the treatment of naïve high-risk MDS/AML and refractory/relapsed AML (75–78), and autophagy inhibitors may be very promising treatment options for hematological malignancies in the future.